A Single-Centre, Observational Study to Evaluate Immune Re- Sponse to Covid-19 Vaccines in Immunocompromised Patients with Haematological Disorders (COVAC-IC)

Authors: Chandra D*, O’Mara L, Bailey L, Aspey M, Asaduzzaman Md, Banavathi K, Lea S, Bowler R, Prasangika J, Ogbolosingha A, Goddard S, Phillips N, Wasim F, Badugama B, Kamran N, Perera K, Bano F, Pillai S, Dyer P, Aquil M, Lewney K, Lee J, Remegoso A, Watts K and Karunanithi K

DOI: 10.23880/aii-16000177

Volume 5, Issue 2

Abstract

To evaluate immunological response to Covid-19 vaccines in immunocompromised haematology patients we compared total Anti-SARS-CoV-2 spike antibody and T cell response in45 immunocompromised haematology patients with 30 healthy adults following 2 doses of Covid-19 vaccine for 3 -5 months at 30-day intervals. We found, non - significant difference in T celland total Anti-SARS-CoV-2 S antibody response between study and control group patients. Conclusions: Though there was a non - significant difference in T cell and total Anti-SARS-CoV-2 S anti body response between immunocompromised patients and healthy controls this did not result in any severe infection or Covid-19 related mortality in our study cohort. We did not identify any patient-specific factor (age, gender), specific haematological condition or treatment as determinant of response. Covid-19 vaccination was well tolerated without major side effects in both groups.

Keywords: Covid-19 vaccines; Immunogenicity; Immunocompromised; Haematological disorders; safety; Efficacy COVACIC, ClinicalTrials.gov Identifier: NCT04805216

View PDF